Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir

Antiviral Research

Volumn 91, Issue 1, 2011, Pages 32-35

  Boutolleau, David ^a   Burrel, Sonia ^a   Agut, Henri ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cytomegalovirus; Ganciclovir; Genotypic antiviral resistance testing; Maribavir; Natural polymorphism; UL97 phosphotransferase

Indexed keywords

BENZIMIDAVIR; GANCICLOVIR; NUCLEOTIDE; PHOSPHOTRANSFERASE;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CYTOMEGALOVIRUS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN IDENTIFICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEOSIDES; SEQUENCE ANALYSIS, DNA;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 79957504008     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.04.015     Document Type: Article

References (29)

1. Boivin G., Goyette N., Gilbert C., Roberts N., Macey K., Paya C., Pescovitz M.D., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., Freeman R., Heaton N., Covington E. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 2004, 189:1615-1618.
2. Boutolleau D., Deback C., Bressollette-Bodin C., Conan F., Aït-Arkoub Z., Imbert-Marcille B.M., Agut H. Genetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factor. Antiviral Ther. 2009, 14:847-852.
3. Boutolleau D., Deback C., Bressollette-Bodin C., Varnous S., Dhedin N., Barrou B., Vernant J.P., Gandjbakhch I., Imbert-Marcille B.M., Agut H. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res. 2009, 81:174-179.
4. Chevillotte M., von Einem J., Meier B.M., Lin F.M., Kestler H.A., Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 2010, 85:318-327.
5. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008, 18:233-246.
6. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Antimicrob. Agents Chemother. 2010, 54:2371-2378.
7. Chou S., Marousek G.I. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 2008, 182:246-253.
8. Chou S., Erice A., Jordan M.C., Vercellotti G.M., Michels K.R., Talarico C.L., Stanat S.C., Biron K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 1995, 171:576-583.
9. Chou S., Guentzel S., Michels K.R., Miner R.C., Drew W.L. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 1995, 172:239-242.
10. Chou S., Lurain N.S., Weinberg A., Cai G.Y., Sharma P.L., Crumpacker C.S. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob. Agents Chemother. 1999, 43:1500-1502. Adult AIDS Trials Group CMV Laboratories.
11. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., Drew W.L. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 2002, 185:162-169.
12. Chou S., Van Wechel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 2005, 49:2710-2715.
13. Chou S., Van Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 2007, 196:91-94.
14. Chou S., Marousek G., Boivin G., Goyette N., Farhan M., Ives J.A., Elston R. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010, 90:1409-1413.
15. Erice J., Borrell N., Li W., Miller W.J., Balfour H.H. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 1998, 178:531-534.
16. Faizi Khan R., Mori S., Eizuru Y., Kumura Ishii K., Minamishima Y. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. Antiviral Res. 1998, 40:95-103.
17. Fillet A.M., Auray L., Alain S., Gourlain S., Imbert B.M., Najioullah F., Champier G., Gouarin S., Carquin J., Houhou N., Garrigue I., Ducancelle A., Thouvenot D., Mazeron M.C. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between III and I. Antimicrob. Agents Chemother. 2004, 48:1865-1868.
18. Foulongne V., Turrière C., Diafouka F., Abraham B., Lastere S., Segondy M. Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virol. 2004, 48:51-55.
19. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
20. He Z., He Y.S., Kim Y., Chu L., Ohmstede C., Biron K.K., Coen D.M. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 1997, 71:405-411.
21. Hu H., Jabs D.A., Forman M.S., Marin B.K., Dunn J.P., Weinberg D.V., Davis J.L. Comparison of cytomegalovirus (CMV) UL97 genes sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J. Infect. Dis. 2002, 185:861-867. for the Cytomegalovirus Retinitis, Viral Resistance Study Group.
22. Ijichi O., Michel D., Mertens T., Miyata K., Eizuru Y. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res. 2002, 53:135-142.
23. Iwasenko J.M., Scott G.M., Rawlison W.D., Keogh A., Mitchell D., Chou S. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J. Med. Virol. 2009, 81:507-510.
24. Lurain N.S., Winberg A., Crumpacker C., Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 2001, 45:2775-2780. for the Adult AIDS Clinical Trials Group CMV Laboratories.
25. Martin M., Gilbert C., Covington E., Boivin G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 2006, 194:579-583.
26. Martin M., Goyette N., Ives J., Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J. Clin. Virol. 2010, 47:321-324.
27. Martin M., Goyette N., Boivin G. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. J. Clin. Virol. 2010, 49:296-298.
28. Prichard M.K. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 2009, 19:215-229.
29. Sanchez Puch S., Ochoa C., Carballal G., Zala C., Cahn P., Brunet R., Salomon H., Videla C. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentine. J. Clin. Virol. 2004, 30:271-275.